Clinical meaning
Autoimmune diseases arise when the immune system loses self-tolerance and mounts an adaptive immune response against the body's own tissues. Under normal conditions, central tolerance eliminates autoreactive T cells in the thymus (negative selection) and autoreactive B cells in the bone marrow, while peripheral tolerance mechanisms including regulatory T cells (Tregs), anergy, and clonal deletion suppress any self-reactive lymphocytes that escape. In autoimmune disease, these tolerance checkpoints fail, allowing autoreactive CD4+ T helper cells and autoreactive B cells to become activated. Autoantibodies produced by B cells can directly damage tissues through complement activation (Type II hypersensitivity, as in autoimmune hemolytic anemia), form immune complexes that deposit in small vessels causing inflammation (Type III hypersensitivity, as in lupus nephritis), or stimulate or block receptor function (as in Graves disease or myasthenia gravis). Cell-mediated autoimmunity involves CD8+ cytotoxic T cells directly attacking target cells (as in Type 1 diabetes destroying pancreatic beta cells) and CD4+ Th1/Th17 cells driving chronic inflammation through cytokine release (TNF-alpha, IL-6, IL-17, IFN-gamma). The NP must understand that autoimmune diseases are often systemic, may overlap (overlap syndromes), and require immunosuppressive therapy that carries significant infection and malignancy risk.